CONSTELLA

This brand name is authorized in Austria, Canada, Estonia, Spain, Finland, Croatia, Ireland, Lithuania, Netherlands, New Zealand, Poland, United Kingdom

Active ingredients

The drug CONSTELLA contains one active pharmaceutical ingredient (API):

1 Linaclotide UNII N0TXR0XR5X - LINACLOTIDE

Linaclotide is a Guanylate Cyclase-C receptor agonist (GCCA) with visceral analgesic and secretory activities. Through its action at GC-C, linaclotide has been shown to reduce visceral pain and increase GI transit in animal models and increase colonic transit in humans. Read about Linaclotide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
CONSTELLA Hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A06AX04		A Alimentary tract and metabolism → A06 Laxatives → A06A Laxatives → A06AX Other laxatives
Discover more medicines within A06AX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02417162, 02417170, 02469510
Country: EE	Ravimiamet	Identifier(s): 1603606, 1603617, 1603628, 1603639, 1744040
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 112801002
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 446436, 530276
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 219676
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1068549, 1068550, 1068552, 1083935
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 127043
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 19835, 19836, 19837
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100125023